Contineum Therapeutics, Inc.
CTNM
NASDAQ·Healthcare·Biotechnology·Mkt cap $661.0M
$16.70
▼ -4.95%
P/E
-9.65
Mkt Cap
$661.0M
52-Wk Range
$8.60–$17.79
52-Week Range
$8.60 - $17.79
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 59.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel brain-penetrant small molecule technology for CNS disorders
- Differentiated oral formulation approach vs. injectable competitors
- Focused pipeline targeting high-unmet medical needs in large markets
- Experienced management team in biotech drug development and commercialization
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Clinical trial progression and positive data readouts for lead programs
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+42.4% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CTNM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of -$0.40 vs -$0.45 consensus (+10.9% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+10.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · $16.00 · May 14, 2026
vs Industry
How CTNM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related